Procrit Could Return To Growth Later This Year, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.
You may also be interested in...
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
J&J Expects EPO Pricing Injunction Ruling In Early 2006
If the court fails to grant a preliminary injunction against Amgen, "tremendous price pressure" will be reinjected into the EPO market, the Procrit marketer tells analysts.